Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia

References

• Narayanan D, Weinberg OK. How I investigate acute myeloid leukemia. Int J Lab Hematol. 2020;42(1):3–15. doi:10.1111/ijlh.13135
   Web of Science ®Google Scholar
• Yang F, Anekpuritanang T, Press RD. Clinical utility of next-generation sequencing in acute myeloid leukemia. Mol Diagn Ther. 2020;24(1):1–13. doi:10.1007/s40291-019-00443-9
   PubMed Web of Science ®Google Scholar
• Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018;59(10):2273–2286. doi:10.1080/10428194.2017.1399312
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kawashima N, Atsuta Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4(1):66–75. doi:10.1182/bloodadvances.2019000709
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.50
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2160–2168. doi:10.1038/leu.2016.126
   PubMed Web of Science ®Google Scholar
• Falini B, Brunetti L, Martelli MP. How I diagnose and treat NPM1-mutated AML. Blood. 2021;137(5):589–599. doi:10.1182/blood.2020008211
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi:10.1056/nejmoa1005143
   PubMed Web of Science ®Google Scholar
• Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170(6):1079–1095.e20. doi:10.1016/j.cell.2017.07.032
   PubMed Web of Science ®Google Scholar
• DiNardo C, Lachowiez C. Acute myeloid leukemia: from mutation profiling to treatment decisions. Curr Hematol Malig Rep. 2019;14(5):386–394. doi:10.1007/s11899-019-00535-7
   PubMed Web of Science ®Google Scholar
• Gong XY, Wang Y, Liu BC, et al. Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements. Chinese Journal of Hematology. 2018;39(1):9–14. doi:10.3760/cma.j.issn.0253-2727.2018.01.003
   Google Scholar
• Van Vlierberghe P, Patel J, Abdel-Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25(1):130–134. doi:10.1038/leu.2010.247
   PubMed Web of Science ®Google Scholar
• Ohgami RS, Ma L, Merker JD, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28(5):706–714. doi:10.1038/modpathol.2014.160
   PubMed Web of Science ®Google Scholar
• Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: challenges and opportunities. Genes Chromosomes Cancer. 2019;58(12):875–888. doi:10.1002/gcc.22796
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27. doi:10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992;80(12):3182–3188. doi:10.1182/blood.V80.12.3182.3182
   Web of Science ®Google Scholar
• Keyhani A, Huh YO, Jendiroba D, et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 2000;24(2):153–159. doi:10.1016/S0145-2126(99)00147-2
   PubMed Web of Science ®Google Scholar
• Kamijo R, Itonaga H, Kihara R, et al. Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. Leuk Res. 2018;65:34–41. doi:10.1016/j.leukres.2017.12.006
   Web of Science ®Google Scholar
• Matsuo T, Kuriyama K, Miyazaki Y, et al. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia. 2003;17(8):1538–1543. doi:10.1038/sj.leu.2403010
   Web of Science ®Google Scholar
• Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis. Blood Rev. 2006;20(2):71–82. doi:10.1016/j.blre.2005.08.002
   PubMed Web of Science ®Google Scholar
• Plesa C, Chelghoum Y, Plesa A, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer. 2008;112(3):572–580. doi:10.1002/cncr.23219
   PubMed Web of Science ®Google Scholar
• Lee YJ, Huang YT, Kim SJ, et al. Adenovirus viremia in adult CD34(+) selected hematopoietic cell transplant recipients: low incidence and high clinical impact. Biol Blood Marrow Transplant. 2016;22(1):174–178. doi:10.1016/j.bbmt.2015.08.019
   PubMed Web of Science ®Google Scholar
• Testa U, Fossati C, Samoggia P, et al. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood. 1996;88(9):3391–3406. doi:10.1182/blood.V88.9.3391.bloodjournal8893391
   Web of Science ®Google Scholar
• Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161–1164. doi:10.1038/sj.leu.2402174
   PubMed Web of Science ®Google Scholar
• Juncà J, Garcia-Caro M, Granada I, et al. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol. 2014;93(9):1483–1489. doi:10.1007/s00277-014-2082-4
   Web of Science ®Google Scholar
• Kita K, Miwa H, Nakase K, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of leukemia/lymphoma. Blood. 1993;81(9):2399–2405. doi:10.1182/blood.V81.9.2399.2399
   PubMed Web of Science ®Google Scholar
• Pinheiro LHS, Trindade LD, Costa F de O, et al. Aberrant phenotypes in acute myeloid leukemia and its relationship with prognosis and survival: a systematic review and meta-analysis. Int J Hematol Oncol Stem Cell Res. 2020;14(4):274–288. doi:10.18502/ijhoscr.v14i4.4484
   Google Scholar
• Kamps WA, Humphrey GB. Heterogeneity among the acute nonlymphocytic leukemias: value of immunophenotype for diagnosis, prognosis, and therapy. Pediatr Hematol Oncol. 1988;5(1):17–28. doi:10.3109/08880018809031247
   PubMed Web of Science ®Google Scholar
• Krasinskas AM, Wasik MA, Kamoun M, Schretzenmair R, Moore J, Salhany KE. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol. 1998;110(6):797–805. doi:10.1093/ajcp/110.6.797
   Web of Science ®Google Scholar
• Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861. doi:10.3324/haematol.2018.191536
   PubMed Web of Science ®Google Scholar
• Keiffer G, Palmisiano N. Acute myeloid leukemia: update on upfront therapy in elderly patients. Curr Oncol Rep. 2019;21(8):71. doi:10.1007/s11912-019-0823-1
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Klepin HD, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Educ Book. 2019;39:421–432. doi:10.1200/edbk_239097
   PubMedGoogle Scholar
• Cher CY, Leung GMK, Au CH, et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016;6(7):e442. doi:10.1038/bcj.2016.51
   PubMed Web of Science ®Google Scholar
• Wang RQ, Chen CJ, Jing Y, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020;9(22):8457–8467. doi:10.1002/cam4.3467
   PubMed Web of Science ®Google Scholar
• Yang J, Yao DM, Ma JC, et al. The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. Tumour Biol. 2016;37(8):10107–10114. doi:10.1007/s13277-015-4716-0
   Google Scholar
• Terada K, Yamaguchi H, Ueki T, et al. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018;57(8):401–408. doi:10.1002/gcc.22542
   Web of Science ®Google Scholar
• Zheng YT, Li BX, Sun YJ, et al. Expression of WT1 gene in bone marrow of patients with acute myeloid leukemia and its influence on prognosis. Journal of Experimental Hematology. 2016;24(3):649-654. doi:10.7534/j.issn.1009-2137.2016.03.003
   Google Scholar